Shortened 8‐Week Course of Sofosbuvir/Ledipasvir Therapy in Adolescents With Chronic Hepatitis C Infection
- 1 November 2019
- journal article
- research article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 69 (5) , 595-598
Abstract
Treatment‐naïve, noncirrhotic adults with chronic hepatitis C virus genotype 1 infection and with viremia levels <6 million IU/mL could be effectively treated with sofosbuvir/ledipasvir for 8 weeks. The aim of this pilot, prospective, open‐label, multicenter study was to evaluate the efficacy and safety of this shortened treatment course in adolescents (≥12 years). The efficacy endpoint was sustained virological response 12 weeks after the end of treatment. Safety was assessed by adverse events and clinical/laboratory data. Fourteen consecutive adolescents (median age 16.5 years, Q1 14.1–Q3 17.4; female 57.1%), vertically infected, were enrolled and treated (June 2018–January 2019). Overall, the end of treatment response and sustained virological response 12 weeks after the end of treatment were 100%. No grade 3 to 4 adverse event or a serious adverse event was observed. Further studies are needed to confirm the optimal efficacy of the shortened 8‐week treatment with sofosbuvir/ledipasvir for treatment‐naïve, noncirrhotic adolescents with chronic hepatitis C virus genotype 1 infection and pretreatment viremia level < 6 million IU/mL.Keywords
Funding Information
- Gilead Sciences
This publication has 12 references indexed in Scilit:
- Hepatitis C virus infection in children and adolescentsThe Lancet Gastroenterology & Hepatology, 2019
- EASL Recommendations on Treatment of Hepatitis C 2018Journal of Hepatology, 2018
- Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B GuidanceClinical Liver Disease, 2018
- Direct-acting antivirals for children and adolescents with chronic hepatitis CThe Lancet Child & Adolescent Health, 2018
- Treatment of Chronic Hepatitis C Virus Infection in ChildrenJournal of Pediatric Gastroenterology and Nutrition, 2018
- The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real‐world experienceAlimentary Pharmacology & Therapeutics, 2018
- Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infectionHepatology, 2017
- The safety and effectiveness of ledipasvir−sofosbuvir in adolescents 12‐17 years old with hepatitis C virus genotype 1 infectionHepatology, 2016
- An Overview of Cirrhosis in ChildrenPediatric Annals, 2016
- P1263 : Global estimate of HCV infection in the pediatric and adolescent populationJournal of Hepatology, 2015